This systematic review and meta-analysis examined data from 1,359 patients with solid tumors. The group included people with gastric cancer, adenocarcinoma of the gastroesophageal junction, and cervical non-small cell lung cancer. Researchers compared cadonilimab plus chemotherapy against monotherapy or combination therapy with targeted agents.
The analysis found positive results for objective response rate, disease control rate, progression-free survival, and overall survival. For patients with gastric or gastroesophageal junction adenocarcinoma, the disease control rate was 0.91. In cervical cancer, the objective response rate was 0.63. When using cadonilimab at 10 mg/kg every three weeks, response rates were high and disease control was excellent.
Safety data showed that adverse events occurred in nearly all patients. Serious treatment-related adverse events happened in about half the patients. Grade 3 immune-related adverse events occurred in roughly 11 percent of patients. The most common side effects included decreased neutrophil count, anemia, and decreased platelet count. The study did not report discontinuation rates or specific funding sources.